Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
Biocytogen and IDEAYA Biosciences have entered into an option and license agreement for a potential first-in-class B7H3/PTK7 bispecific antibody drug conjugate (BsADC) program. The agreement grants IDEAYA an option for an exclusive worldwide license for the program, which targets B7H3/PTK7 co-expression found in multiple solid tumor types. Biocytogen will receive an upfront fee and potential milestone payments totaling $406.5 million, including $100 million in development and regulatory milestones, plus single-digit royalties on net sales.
The BsADC program has the potential to be developed as a monotherapy and in combination with IDEAYA's DNA Damage Repair (DDR) pipeline, including IDE161 (PARG inhibitor). A development candidate nomination is targeted for H2 2024. This collaboration leverages Biocytogen's RenLite® platform and proprietary linker-payload technology to enhance ADC precision and potency.
Biocytogen e IDEAYA Biosciences hanno stipulato un accordo di opzione e licenza per un potenziale farmaco congiugato di anticorpi bispecifici B7H3/PTK7 di prima classe (BsADC). L'accordo concede a IDEAYA un'opzione per una licenza esclusiva a livello mondiale per il programma, che mira alla coespressione di B7H3/PTK7 riscontrata in più tipi di tumori solidi. Biocytogen riceverà un compenso iniziale e potenziali pagamenti legati ai traguardi che ammontano a 406,5 milioni di dollari, inclusi 100 milioni di dollari per traguardi di sviluppo e normativi, oltre a royalties a un cifra singola sulle vendite nette.
Il programma BsADC ha il potenziale per essere sviluppato come monoterapia e in combinazione con il pipeline di Riparazione del Danno al DNA (DDR) di IDEAYA, inclusa IDE161 (inibitore di PARG). Una nomina di candidato allo sviluppo è prevista per il secondo semestre del 2024. Questa collaborazione sfrutta la piattaforma RenLite® di Biocytogen e la tecnologia proprietaria di linker-payload per migliorare la precisione e la potenza degli ADC.
Biocytogen y IDEAYA Biosciences han firmado un acuerdo de opción y licencia para un potencial programa de conjugado de anticuerpos biespecíficos B7H3/PTK7 de primera clase (BsADC). El acuerdo otorga a IDEAYA una opción para una licencia mundial exclusiva para el programa, que se enfoca en la coexpresión de B7H3/PTK7 encontrada en múltiples tipos de tumores sólidos. Biocytogen recibirá una tarifa inicial y pagos por hitos potenciales que suman 406,5 millones de dólares, incluidos 100 millones de dólares en hitos de desarrollo y regulatorios, además de regalías de un solo dígito sobre las ventas netas.
El programa BsADC tiene el potencial de desarrollarse como monoterapia y en combinación con la línea de tratamiento de Reparación de Daños en el ADN (DDR) de IDEAYA, incluyendo IDE161 (inhibidor de PARG). Se espera que la nominación de un candidato para desarrollo se realice en el segundo semestre de 2024. Esta colaboración aprovecha la plataforma RenLite® de Biocytogen y la tecnología patentada de linkers y fármacos para mejorar la precisión y potencia de los ADC.
Biocytogen과 IDEAYA Biosciences는 잠재적인 1종 최초의 B7H3/PTK7 이중 특이성 항체 약물 접합체(BsADC) 프로그램에 대한 옵션 및 라이선스 계약을 체결했습니다. 이 계약은 IDEAYA에게 이 프로그램에 대한 독점적인 전세계 라이선스 옵션을 부여하며, 이는 여러 고형 종양에서 발견되는 B7H3/PTK7의 공동 발현을 목표로 합니다. Biocytogen은 선금과 최대 4억 6천 5백만 달러에 달하는 이정표 금액을 받을 예정이며, 여기에는 1억 달러의 개발 및 규제 이정표가 포함되고 순판매에 대한 단일 숫자의 로열티가 추가됩니다.
BsADC 프로그램은 IDEAYA의 DNA 손상 복구(DDR) 파이프라인과 병용하거나 단일 요법으로 개발될 가능성이 있습니다, 여기에는 IDE161(인히비터 PARG)이 포함됩니다. 개발 후보자 지명은 2024년 하반기로 예정되어 있습니다. 이 협업은 Biocytogen의 RenLite® 플랫폼과 독점적인 링커-페이로드 기술을 활용하여 ADC의 정확성과 효능을 향상시킵니다.
Biocytogen et IDEAYA Biosciences ont conclu un accord d'option et de licence pour un potentiel médicament conjugué d'anticorps bispécifiques B7H3/PTK7 de première classe (BsADC). Cet accord accorde à IDEAYA une option pour une licence exclusive mondiale pour le programme, qui cible la co-expression B7H3/PTK7 retrouvée dans plusieurs types de tumeurs solides. Biocytogen recevra une redevance initiale et des paiements d'étapes potentiels totalisant 406,5 millions de dollars, incluant 100 millions de dollars en étapes de développement et réglementaires, ainsi que des redevances à un chiffre sur les ventes nettes.
Le programme BsADC a le potentiel d'être développé en tant que monothérapie et en combinaison avec le pipeline de Réparation des Dommages à l'ADN (DDR) d'IDEAYA, y compris IDE161 (inhibiteur de PARG). Une nomination de candidat au développement est prévue pour le second semestre 2024. Cette collaboration exploite la plateforme RenLite® de Biocytogen et la technologie propriétaire de lien-charge utile pour améliorer la précision et la puissance des ADC.
Biocytogen und IDEAYA Biosciences haben eine Options- und Lizenzvereinbarung für ein potenzielles erster seiner Art B7H3/PTK7 bispezifisches Antikörper-Wirkstoff-Konjugat (BsADC) Programm abgeschlossen. Die Vereinbarung gewährt IDEAYA eine Option auf eine exklusive weltweite Lizenz für das Programm, das auf die Co-Expression von B7H3/PTK7 abzielt, die in mehreren soliden Tumorarten vorkommt. Biocytogen wird eine Vorauszahlung und potenzielle Meilensteinzahlungen in Höhe von insgesamt 406,5 Millionen Dollar erhalten, einschließlich 100 Millionen Dollar in Entwicklungs- und Regulierungsmeilensteinen sowie Einzelhandelsprovisionen auf den Nettoumsatz.
Das BsADC-Programm hat das Potenzial, als Monotherapie und in Kombination mit IDEAYAs DNA Damage Repair (DDR) Pipeline entwickelt zu werden, einschließlich IDE161 (PARG-Inhibitor). Eine Nominierung eines Entwicklungskandidaten ist für die zweite Hälfte von 2024 geplant. Diese Zusammenarbeit nutzt Biocytogens RenLite®-Plattform und proprietäre Linker-Payload-Technologie, um die Genauigkeit und Wirksamkeit von ADCs zu verbessern.
- Potential first-in-class B7H3/PTK7 BsADC program with applications in multiple solid tumor types
- Total potential payments of $406.5 million, including $100 million in development and regulatory milestones
- Single-digit royalties on net sales for Biocytogen
- Combination opportunities with IDEAYA's DNA Damage Repair (DDR) pipeline
- Development candidate nomination targeted for H2 2024
- None.
Insights
This collaboration between Biocytogen and IDEAYA Biosciences marks a significant step in the development of a potentially groundbreaking cancer therapy. The B7H3/PTK7 bispecific antibody-drug conjugate (BsADC) program targets a unique combination of proteins expressed in various solid tumors, potentially offering a new treatment avenue for patients with options.
The deal structure, with an upfront fee and potential milestone payments totaling
The potential synergy with IDEAYA's DNA Damage Repair (DDR) pipeline, particularly the PARG inhibitor IDE161, could enhance the therapeutic efficacy and broaden the application of this BsADC. This aligns with the growing trend of combination therapies in oncology, potentially increasing the program's value proposition.
For Biocytogen, this deal validates their RenLite® platform and proprietary linker-payload technology, potentially attracting more partnerships and bolstering their position in the competitive ADC landscape. For IDEAYA, it expands their portfolio beyond small molecule DDR-based therapies, diversifying their approach to precision oncology.
Investors should monitor the progress towards the development candidate nomination in H2 2024, as this will be a important milestone in assessing the program's potential. The collaboration also highlights the increasing interest in bispecific ADCs as a promising modality in cancer treatment, potentially signaling a broader industry trend.
The option and license agreement between Biocytogen and IDEAYA Biosciences represents a significant financial opportunity for both companies. The deal structure, with a total potential value of
For Biocytogen, this agreement provides immediate revenue through the upfront fee and potential future cash flows from milestone payments and royalties. This deal structure mitigates some of the financial risks associated with drug development while still maintaining upside potential. The single-digit royalties on net sales, if the product reaches the market, could provide a steady long-term revenue stream.
IDEAYA's investment in this program aligns with their strategy to expand their oncology portfolio. While the upfront costs are not disclosed, the potential
The market potential for this therapy, given its applicability across multiple solid tumor types, could be substantial. However, it's important to note that the program is still in early stages, with significant R&D costs and regulatory hurdles ahead. The targeted development candidate nomination in H2 2024 provides a near-term milestone for investors to gauge progress.
This collaboration also highlights the increasing value of innovative platforms in biotechnology. Biocytogen's RenLite® platform and proprietary linker-payload technology could attract further partnerships, potentially creating additional revenue streams. For both companies, this deal could enhance their attractiveness to investors and potentially impact their valuation multiples in the biotechnology sector.
- Biocytogen granted IDEAYA an option for an exclusive worldwide license for potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program
- B7H3/PTK7 co-expression found in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, and head and neck cancers
- Rational combo opportunities with IDEAYA’s DNA Damage Repair (DDR) pipeline, including IDE161 (PARG)
- Targeting development candidate nomination in H2 2024
“We are thrilled to announce our collaboration with IDEAYA to explore the promising combination of our potential first-in-class ADC and IDEAYA’s DDR small molecules,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This partnership leverages our cutting-edge RenLite® platform and proprietary linker-payload technology to enhance the precision and potency of ADCs. IDEAYA's strong determination and rich experience in drug development make us confident that this therapy could be rapidly advanced to benefit patients.”
“The potential first-in-class B7H3/PTK7 topo-I-payload BsADC program has the potential to be developed as a monotherapy agent in multiple solid tumor types, and advances IDEAYA’s broader corporate strategy to enable wholly-owned first-in-class rational combinations at the intersection of ADCs and small molecule DDR-based therapies to deliver greater benefit for patients,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.
The agreement grants IDEAYA an option for an exclusive worldwide license from Biocytogen for a potential first-in-class B7H3/PTK7 topo-I-payload BsADC program. B7H3/PTK7 has been found to be co-expressed in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, and head and neck cancers, among others.
Under the terms of the agreement, Biocytogen will receive an upfront fee and upon an option exercise by IDEAYA, be entitled to receive an option exercise fee, development and regulatory milestones and commercial milestone payments, as well as single-digit royalties on net sales. Total potential upfront, option exercise and milestone payments equal an aggregate of
Based on preclinical data, the potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program has the potential to be developed as a monotherapy agent and used in combination with multiple programs in IDEAYA’s pipeline targeting DDR-based therapies, including PARG inhibitor IDE161. A development candidate nomination for the B7H3/PTK7 topoisomerase-I-inhibitor payload BsADC program is targeted for the second half of 2024.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/ RenLite®/ RenNano®/ RenTCR-mimicTM ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA’s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731406265/en/
Biocytogen Contacts
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
Source: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
FAQ
What is the focus of the agreement between Biocytogen and IDEAYA Biosciences?
What is the total potential value of the agreement for Biocytogen?
When is the development candidate nomination for the B7H3/PTK7 BsADC program targeted?
How does this agreement align with IDEAYA's (IDYA) corporate strategy?
What types of cancers show B7H3/PTK7 co-expression according to the press release?
